Table 2 Anti-VEGF treatment outcome in patients receiving insulin or OHA for DM, stratified by baseline vision
Insulin | OHA | P value* (95% CI) | |
|---|---|---|---|
BCVA ≥ 70 approxETDRS letters | N = 75 | N = 32 | |
Baseline BCVA (approxETDRS letters) | 73.53 (3.61) | 73.03 (4.02) | 0.546 (-1.15, 2.15) |
Final BCVA (approxETDRS letters) | 73.88 (5.81) | 73.66 (6.51) | 0.867 (-2.45, 2.89) |
BCVA change (approxETDRS letters) | 0.35 (6.08) | 0.62 (6.99) | 0.689 (-4.99, 1.00) |
Baseline CMT (microns) | 345.84 (58.56) | 356.19 (81.10) | 0.517 (-42.27, 21.57) |
Final CMT (microns) | 302.73 (47.29) | 316.16 (69.98) | 0.326 (-40.68, 13.83) |
CMT change (microns) | -43.09 (63.88) | -40.03 (86.81) | 0.624 (-32.00, 21.00) |
Injection number | 8.21 (2.99) | 8.03 (3.08) | 0.779 (-1.11, 1.47) |
BCVA < 70 approxETDRS letters | N = 62 | N = 29 | |
Baseline BCVA (approxETDRS letters) | 52.65 (10.86) | 54.17 (11.36) | 0.547 (-6.58, 3.53) |
Final BCVA (approxETDRS letters) | 61.61 (15.28) | 57.52 (17.96) | 0.294 (-3.66, 11.85) |
BCVA change (approxETDRS letters) | 8.97 (13.99) | 3.34 (15.10) | 0.063 (0.00, 10.00) |
Baseline CMT (microns) | 422.05 (124.99) | 441.28 (128.52) | 0.505 (-76.69, 38.24) |
Final CMT (microns) | 338.45 (84.56) | 330 (106.18) | 0.708 (-36.26, 91.62) |
CMT change (microns) | -83.60 (131.88) | -111.28 (145.80) | 0.259 (-26.00, 81.99) |
Injection number | 8.31 (3.13) | 7.97 (3.51) | 0.657 (-1.19, 1.87) |